alprazolam has been researched along with Neonatal Abstinence Syndrome in 2 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
Neonatal Abstinence Syndrome: Fetal and neonatal addiction and withdrawal as a result of the mother's dependence on drugs during pregnancy. Withdrawal or abstinence symptoms develop shortly after birth. Symptoms exhibited are loud, high-pitched crying, sweating, yawning and gastrointestinal disturbances.
Excerpt | Relevance | Reference |
---|---|---|
"The newborn of a mother reporting alprazolam use during pregnancy presented with respiratory distress and clinical features consistent with neonatal withdrawal syndrome or neonatal sepsis of vertical transmission." | 7.74 | Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. ( García-Algar, O; López-Vílchez, MA; Martín, I; Mur, A; Pacifici, R; Pellegrini, M; Pichini, S; Rossi, S, 2007) |
" In this study, the association between NAS and plasma alprazolam concentration was examined using the measured neonatal concentrations in the time series as well as simulated plasma concentrations of pregnant woman and neonate by physiologically based pharmacokinetic (PBPK) modeling." | 5.51 | Pharmacokinetic assessment of alprazolam-induced neonatal abstinence syndrome using physiologically based pharmacokinetic model. ( Fujioka, K; Fukushima, S; Hashimoto, M; Iijima, K; Mishima, Y; Yamakawa, K; Yamamoto, K; Yano, I, 2019) |
"The newborn of a mother reporting alprazolam use during pregnancy presented with respiratory distress and clinical features consistent with neonatal withdrawal syndrome or neonatal sepsis of vertical transmission." | 3.74 | Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. ( García-Algar, O; López-Vílchez, MA; Martín, I; Mur, A; Pacifici, R; Pellegrini, M; Pichini, S; Rossi, S, 2007) |
" In this study, the association between NAS and plasma alprazolam concentration was examined using the measured neonatal concentrations in the time series as well as simulated plasma concentrations of pregnant woman and neonate by physiologically based pharmacokinetic (PBPK) modeling." | 1.51 | Pharmacokinetic assessment of alprazolam-induced neonatal abstinence syndrome using physiologically based pharmacokinetic model. ( Fujioka, K; Fukushima, S; Hashimoto, M; Iijima, K; Mishima, Y; Yamakawa, K; Yamamoto, K; Yano, I, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Yamamoto, K | 1 |
Fukushima, S | 1 |
Mishima, Y | 1 |
Hashimoto, M | 1 |
Yamakawa, K | 1 |
Fujioka, K | 1 |
Iijima, K | 1 |
Yano, I | 1 |
García-Algar, O | 1 |
López-Vílchez, MA | 1 |
Martín, I | 1 |
Mur, A | 1 |
Pellegrini, M | 1 |
Pacifici, R | 1 |
Rossi, S | 1 |
Pichini, S | 1 |
2 other studies available for alprazolam and Neonatal Abstinence Syndrome
Article | Year |
---|---|
Pharmacokinetic assessment of alprazolam-induced neonatal abstinence syndrome using physiologically based pharmacokinetic model.
Topics: Alprazolam; Female; Humans; Hypnotics and Sedatives; Models, Biological; Neonatal Abstinence Syndrom | 2019 |
Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Diagnosis, Differential; Female; Fetal Blood; Hair; Humans; | 2007 |